Digipath
Home > Boards > US OTC > Medical - Healthcare >

BioCorRx Inc. (BICXD)

BICXD RSS Feed
Add BICXD Price Alert      Hide Sticky   Hide Intro
Moderator: Pip611, Swisher27
Search This Board: 
Last Post: 1/21/2019 7:41:53 PM - Followers: 145 - Board type: Free - Posts Today: 7

 

 

About BioCorRx

Program Overview

BioCorRx (OTCBB: BICX) is an alcohol treatment and rehabilitation company on the leading edge of alcohol addiction treatment. The company has developed a treatment program that is used by various licensed alcohol addiction clinics throughout the United States.

The program consists of two components:BioCorRx has the worldwide rights (except in Australia and New Zealand) to a highly effective, proprietary implant formulation of the FDA-approved drug, naltrexone. After being surgically implanted by a medical professional, the naltrexone implant significantly reduces cravings for alcohol for as long as a year in some patients, depending on individual metabolism rates.BioCorRx also owns a life coaching program that is tailored specifically to alcoholics. Once a patient has received the implant, they are encouraged to enter the life coaching program to maximize results.

BioCorRx’s revolutionary alcohol treatment program has an 85% success rate as reported by patients in routine telephone and face to face interviews. The implant is administered as an outpatient procedure, and in most cases, patients do not need to miss more than one day of work. They are then able to enter the private life coaching program without co-workers or family members knowing, unless they so choose.

Technology

Naltrexone is a medication that blocks the effects of drugs known as opioids and was approved by the FDA in 1995 for the treatment of alcohol dependence.

Learn more about the side effects of naltrexone.

Naltrexone blocks the parts of the brain that "feel pleasure” when patients use alcohol. When these areas of the brain are blocked, patients feel significantly less cravings for alcohol and even if alcohol is used, the effects of it will be extremely limited - making sobriety the only option. Once medical intervention has reduced the physical need for alcohol, the program goes on to address the patient's psychological needs. The combination of these treatments has resulted in the highest chance of sobriety.

naltrexone implant

While other companies use naltrexone in their treatments, the drug is typically administered in oral or injection form, requiring their patients to be responsible for taking the medication or scheduling an appointment.

While some patients do well with the oral formulation, there is a drawback that it must be taken daily and a patient whose craving becomes overwhelming can obtain the euphoria simply by skipping a dose before resuming abuse. Patients who received the program developed by BioCorRx are treated with a slow release dose that can last up to year in many patients (depending on various factors such as metabolism rates), which gives the patients a higher success rate for the treatment of alcoholism.

The outpatient naltrexone implant procedure can take as little as 20 minutes under local anesthetic in some cases. Most patients can return to work or their daily routine in the same day, without the cravings for alcohol.

Mission, Vision, Values

Mission

BioCorRx is focused on providing leadership and innovation for the treatment of alcoholism by offering a high-quality, comprehensive and cost-effective recovery program that allows patients and their loved ones to celebrate freedom from the cycle of alcohol addiction. Our program is built on a strong foundation of experience and practice, allowing for an improved quality of life for recovering alcoholics.

Vision

BioCorRx strives to be the preeminent, long-term alcohol recovery program used by treatment centers around the world for alcoholics, as well as their family and friends. By providing patients a "Fresh Start" on life, they have the opportunity to live happier, healthier, more productive lives away from the damaging impact of alcohol. We have built an organization that is committed to nurturing research for cutting-edge alcohol recovery technologies and integrating those technologies with comprehensive alcohol recovery treatment programs.

Values

BioCorRx provides the opportunity and tools to treatment centers so they can help patients live happier, healthier, and more productive lives to those suffering from alcohol addiction (as well as their family and friends) by helping them break the addiction cycle and live alcohol-free. We want patients to celebrate freedom from the past and hope for the future. Our team consists of physicians, coaches, founders and management that are committed to providing high-quality services and adherence to ethical care.

Our goal is to give our treatment center partners the ability to deliver our program in a timely, warm and compassionate way to give patients, as well as their families and friends, peace of mind. To achieve this, BioCorRx has built its program around highly-qualified alcohol addiction specialists and effective treatment solutions.

We are committed to quality and continuous improvement in order to meet our partners’ needs for an individualized program dedicated to alcohol addiction recovery.

Investors Overview

BioCorRx is uniquely poised to gain significant market share of the $22 billion annual alcohol treatment market in the US.

More than 7% of the US population ages 18 years and older or 13.8 million Americans have problems with drinking, including 8.1 million people who suffer from alcoholism. And the costs financially are staggering. Alcohol dependency and abuse costs the US over $220 billion a year. For the sake of comparison, this is greater than the amount of money spent to combat cancer ($196 billion) and obesity ($133 billion).

BioCorRx intends to distribute the program to a new clinic in the United States every 60 to 90 days. Clinics using our program are also holding discussions with major health insurance providers to pay for all or a portion of the treatment fees.

Business Model

BioCorRx’s research has discovered that demand for its services are high and that growth in highly marketed segments of the population may be achieved through partnering with additional clinic sites. The company is also exploring the sub-licensing of the program to select regions of the US and internationally.

BioCorRx's goal is to meet its growth targets through licensing opportunities by promoting its naltrexone implant product and counseling service model to existing medical clinics and treatment centers that will purchase the program and/or product from the company. In addition, Fresh Start Private intends to open corporately owned clinics in select key markets where it is deemed appropriate.

Stock Price & Charts

BioCorRx is a fully reporting company. Financial reports and other reports are available for view or by visiting the OTCBB.com online website. Audited financial reports are available quarterly.

Company Structure Details

  • Legal name: BioCorRx
    Sector: Healthcare
    Industry: Specialized Health Services
    Full Time Employees: 4
    Public Company: SEC Reporting and fully audited
    Symbol: BICX
    Exchange: OTCBB
    Outstanding: 117,800,000
    Authorized: 200,000,000
    CUSIP: 35804J102
    NAICS Code: 623220
    SIC Number: 8093
    Transfer Agent: Columbia Stock Transfer Company, 1869 E. Seltice Way #292, Post Falls, ID 83854 Tel (208) 664-3544
    CIK: 0001443863
    EIN: 26-1972677
    Year End: December 31
    State of incorporation: Nevada
    Products: Alcohol rehabilitation, exclusive naltrexone implant technology
    Address: 601 North Parkcenter Drive, Suite 103, Santa Ana, CA 92705 USA
    Investors: 858-381-4677
    Email: investors@biocorrx.com
    Website: www.biocorrx.com
Watch Jeremy Miller on Fox News!
https://www.youtube.com/watch?v=kVKgWi3_t5Y

<iframe width="560" height="315" src="; frameborder="0" allowfullscreen></iframe>www.youtube.com/embed/xhJrYqsV0VQ

<iframe width="560" height="315" src="https://www.youtube.com/watch?v=kVKgWi3_t5Y" frameborder="0" allowfullscreen></iframe>


 

BICX Chart

Key Executives

Kent Emry - CEO, Director
Brady Granier -COO, Director
Lourdes Felix -CFO, Director
Dr. Jorge Andrade, Jr. - Director
Neil Muller -Co-Founder and President, Director 

Locations
Locations of independently owned clinics using our Fresh Start Program

Start Fresh Recovery
720 N. Tustin Ave.
Suite 206
Santa Ana, CA 92705
714-541-6100
800-916-1099
www.startfreshrecovery.com 
www.stopdrinkingUSA.com

Start Fresh Executive Recovery
367 E Virginia Ave
Phoenix, AZ 85004
855-393-HOPE (4673)
www.ExecutiveRecovery.net 

Fresh Start Private Florida
1415 Panther Lane
Suites 313-320
Naples, FL 34109
800-985-7574
www.FreshStartPrivateFlorida.com 

Start Fresh Alcohol Recovery Center
2827 S. 88th St
Omaha NE 68124
402-884-1221
www.startfreshNE.com

Coming Soon!

• San Francisco, California
• Chandler, Arizona
• North Scottsdale, Arizona
• Connecticut

Insider Interview Links

December 2, 2013 - thewallstreetanalyzer.com Interview with Brady Granier COO
November 14, 2013 - SmallCapVoice Interview with Kent Emry CEO
October 2, 2013 - SmallCapVoice Interview with Brady Granier COO

 

 

Digipath
BICXD
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
PostSubject
#7544  Sticky Note VIVITROL is injectable naltrexone produced by Alkermes plc Pip611 09/09/16 05:15:47 PM
#11907   Totally agree with you on this. I'm in Admtiger 01/21/19 07:41:53 PM
#11906   There are 3 ways to get listed on NASDAQ. drugmanrx 01/21/19 03:53:51 PM
#11905   Can you elaborate why re NAS, Jon Boyz 01/21/19 11:54:01 AM
#11904   They currently don't meet the listing requirements for NASDAQ. drugmanrx 01/21/19 11:01:36 AM
#11903   Yep, but they showed me (us) some money Fido 01/21/19 10:36:31 AM
#11902   no, they are not uplisting tomorrow. if they lucky,mydog 01/21/19 09:52:30 AM
#11901   100:1 reverse stanggt 01/21/19 07:48:23 AM
#11900   Not sure if anyone else uses TD Ameritrade Leshrac528 01/20/19 11:29:33 PM
#11899   The rest are probably going to bail. lucky,mydog 01/20/19 10:26:15 PM
#11898   Thanks everyone for the informative posts on the Winginitasusual 01/20/19 09:05:51 PM
#11897   what? the sec has no such thing as lucky,mydog 01/20/19 07:36:06 PM
#11896   It's a deadline imposed by the SEC actually. Swisher27 01/20/19 07:21:09 PM
#11895   Crazy talk, it a self imposed deadline. drugmanrx 01/20/19 06:45:29 PM
#11894   "The granting of discretionary authority to the Board Swisher27 01/20/19 06:02:40 PM
#11893   Okay. Appreciate your points, but disagree. Furthermore, Jon Boyz 01/20/19 05:38:28 PM
#11892   I believe the nasdaq requires $4 minimum to Leshrac528 01/20/19 04:35:50 PM
#11891   Should have let this run and then time Jon Boyz 01/20/19 04:24:40 PM
#11890   Regardless of the mechanics of the split, I’m Thomasthomas 01/20/19 03:55:52 PM
#11889   Ohhhhh okay that’s awesome! I thought the RS Joshthebeast24 01/20/19 03:50:29 PM
#11888   That would be 16, if I’m not mistaken. Thomasthomas 01/20/19 01:31:50 PM
#11887   So 8 dollars? Joshthebeast24 01/20/19 01:25:10 PM
#11886   Hoping for double! Thomasthomas 01/20/19 12:20:12 PM
#11885   JonBoy, Care to expound on why? One line agreement Leshrac528 01/20/19 12:08:42 PM
#11884   I’m with Drugman on this one. Jon Boyz 01/20/19 11:26:49 AM
#11883   Very well said. It does help when you Joshthebeast24 01/20/19 10:13:15 AM
#11882   Can someone please explain this notion of the Leshrac528 01/19/19 09:52:38 PM
#11881   Im sure management considered waiting to do the RBC- 01/19/19 08:18:19 PM
#11880   Sorry disagree. drugmanrx 01/19/19 07:31:05 PM
#11879   As far as the timing goes, management didn’t RBC- 01/19/19 06:31:34 PM
#11878   I have to agree the timing of the drugmanrx 01/19/19 05:30:07 PM
#11877   Very true! Hopefully it all comes out as Joshthebeast24 01/19/19 12:20:42 PM
#11876   I don’t have facts and figures on that, msw1221 01/19/19 12:14:29 PM
#11875   I really hope you’re right! I just Joshthebeast24 01/19/19 11:16:01 AM
#11874   I don’t think $1 would satisfy the kinds msw1221 01/19/19 11:04:21 AM
#11873   I mean I’m in this for the long Joshthebeast24 01/19/19 10:56:05 AM
#11872   I agree, yesterday’s dual announcement of stock split msw1221 01/19/19 10:39:31 AM
#11871   Got the grant so BICX102 is paid for! RBC- 01/19/19 10:20:58 AM
#11870   Dilution means revolution. rocky1088 01/19/19 08:16:27 AM
#11869   Brady had stated that r/s has been on Jon Boyz 01/19/19 08:02:11 AM
#11868   Yeah I feel the same way. I’ve been Joshthebeast24 01/18/19 10:52:59 PM
#11867   Brady doesn’t know what he’s doing. Jon Boyz 01/18/19 07:54:58 PM
#11866   Learning how to do the "next right Winginitasusual 01/18/19 07:30:55 PM
#11865   Congrats!!! If I were yinz I would scream Kizersosae 01/18/19 04:41:23 PM
#11864   BICX changed to BICXD, one for 100 reverse split: Renee 01/18/19 04:35:01 PM
#11863   On January 17, 2019, the Company received a GaryWinthorpe 01/18/19 04:30:46 PM
#11862   Stock reverse split PLUS grant award!! msw1221 01/18/19 04:30:24 PM
#11861   They got the grant. 5.5 million over 2 years! Pip611 01/18/19 04:29:42 PM
#11860   https://hinewulm.com/2019/01/14/tributary-capital-management-boosted-its-interce GaryWinthorpe 01/18/19 04:24:21 PM
#11859   Granier's plan to uplist. Swisher27 01/18/19 01:50:09 PM
#11858   Effective/Ex Date/Time01/22/2019 00:00:00 Admtiger 01/18/19 12:47:52 PM
PostSubject